Roche is hungry, not starving for M&A

Share this article:

Roche has no immediate plans for a mega deal. CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships, a strategy it has had in place for some time, and which includes its July purchase of biotech Seragon for $1.7 billion.

Schwan says Roche evaluates potential moves based on how it would affect the balance between external opportunities and internal ones. “It can't be that we have to put important internal opportunities on ice because of too-expensive acquisitions,” he says.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.